Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Presented as correlation coefficient (p-value).ProteinAccessionAMHAndrostenedioneTestosteroneProgesteroneEstradiolEstriolEstroneEstrone-3-sulphateGranzyme MP51124−0.574 (0.0027)−0.444 (0.0262)−0.424 (0.0349)UnknownH0YCG3−0.541 (0.0053)−0.505 (0.0101)−0.486 (0.0138)−0.500 (0.0109)UnknownH0YJW9−0.498 (0.0113)−0.589 (0.0020)−0.483 (0.0144)−0.403 (0.0455)Complement component C8 gamma chainP07360−0.431 (0.0317)−0.530 (0.0065)−0.436 (0.0292)−0.403 (0.0455)ProperdinP279180.417 (0.0383)Serum amyloid PP02743−0.405 (0.0443)Fanconi associated nucleaseQ9Y2M0−0.404 (0.0452)Heparin cofactor 2P05546−0.402 (0.0463)−0.410 (0.0416)−0.430 (0.0319)Fetuin-BQ9UGM5−0.397 (0.0493)−0.404 (0.0451)−0.435 (0.0298)C4b-binding protein alpha chainP04003−0.583 (0.0022)Apolipoprotein C-IIIP026560.525 (0.0071)0.645 (4.96E-04)0.430 (0.0319)0.507 (0.0097)Insulin-like growth factor-binding protein complex acid labile subunitP35858−0.523 (0.0073)−0.459 (0.0209)Ficolin-3O75636−0.466 (0.0190)−0.442 (0.0270)Keratin type I cytoskeletal 9P35527−0.434 (0.0304)−0.526 (0.0070)Phosphatidylinositol 4.5-bisphosphate 3-kinase catalytic subunit alphaP42336−0.430 (0.0317)Prostaglandin-H2 D-isomeraseP41222−0.422 (0.0357)−0.399 (0.0483)Pregnancy-specific beta-1-glycoprotein 3Q16557−0.417 (0.0379)−0.513 (0.0088)KallistatinP29622−0.416 (0.0384)Sex hormone-binding globulinP04278−0.416 (0.0388)−0.406 (0.0442)TetranectinP05452−0.413 (0.0402)−0.555 (0.0040)−0.412 (0.0407)−0.424 (0.0347)Complement C3P01024;Q96MT0−0.411 (0.0415)Zinc-alpha-2-glycoproteinP25311−0.400 (0.0474)−0.477 (0.0158)Inactive dipeptidyl peptidase 10Q8N6080.700 (9.96E-05)0.646 (0.0005)0.479 (0.0155)AttractinO758820.566 (3.17E-03)Inter-alpha-trypsin inhibitor heavy chain H4Q146240.560 (3.62E-03)Complement factor H-related protein 5Q9BXR60.404 (4.52E-02)Pappalysin-1Q132190.568 (0.0031)Platelet factor 4P02766−0.530 (0.0064)Vitamin K-dependent protein CP04070−0.460 (0.0207)−0.430 (0.0318)Vitamin D-binding proteinP02774;Q5VZM2−0.448 (0.0248)HLA class II histocompatibility antigen DP beta 1 chainP04440−0.447 (0.0252)Extracellular matrix protein 1Q16610−0.438 (0.0286)CeruloplasminP00450−0.437 (0.0289)Beta-Ala-His dipeptidaseQ96KN2−0.425 (0.0341)Keratin type II cytoskeletal 1P04264−0.409 (0.0422)Thyroxine-binding globulinP05543−0.574 (0.0027)−0.509 (0.0093)−0.463 (0.0197)Pregnancy-specific beta-1-glycoprotein 9Q008870.483 (0.0145)0.475 (0.0164)ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2Q105880.433 (0.0308)0.588 (0.0020)Complement component C8 beta chainP07358−0.411 (0.0414)Complement C1r subcomponent-like proteinQ9NZP80.440 (0.0278)Actin cytoplasmic 1P60709;P632610.406 (0.0442)Alpha-1-antichymotrypsinP01011−0.463 (0.0198)Pregnancy-specific beta-1-glycoprotein 1P114640.449 (0.0242)Pregnancy-specific beta-1-glycoprotein 5Q152380.477 (0.0158)
Source: Correlation analysis. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The women were diagnosed according to the Rotterdam criteria, meaning that at least two of the following criteria were present: (1) polycystic ovaries by ultrasonography, (2) oligo: or amenorrhoea and (3) hyperandrogenism, either biochemical (elevated testosterone, androstenedione or elevated free androgen index) or clinical (hirsutism, Ferriman-Gallwey score > 8).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Thromboinflammatory changes in plasma proteome of pregnant women with PCOS detected by quantitative label-free proteomics
Study design awaiting verification · Scientific Reports · 2019
Original publication title
Thromboinflammatory changes in plasma proteome of pregnant women with PCOS detected by quantitative label-free proteomics
© The Author(s) 2019
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Polycystic ovary syndrome (PCOS) is the most common endocrinological disorder of fertile-aged women. Several adverse pregnancy outcomes and abnormalities of the placenta have been associated with PCOS. By using quantitative label-free proteomics we investigated whether changes in the plasma proteome of pregnant women with PCOS could elucidate the mechanisms behind the pathologies observed in PCOS pregnancies. A total of 169 proteins with ≥2 unique peptides were detected to be differentially expressed between women with PCOS (n = 7) and matched controls (n = 20) at term of pregnancy, out of which 35 were significant (p-value < 0.05).
A pathway analysis revealed that networks related to humoral immune responses, inflammatory responses, cardiovascular disease and cellular growth and proliferation were affected by PCOS. Classification of cases and controls was carried out using principal component analysis, orthogonal projections on latent structure-discriminant analysis (OPLS-DA), hierarchical clustering, self-organising maps and ROC-curve analysis. The most significantly enriched proteins in PCOS were properdin and insulin-like growth factor II. In the dataset, properdin had the best predictive accuracy for PCOS (AUC = 1). Additionally, properdin abundances correlated with AMH levels in pregnant women.
Authors’ abstract
Polycystic ovary syndrome (PCOS) is the most common endocrinological disorder of fertile-aged women. Several adverse pregnancy outcomes and abnormalities of the placenta have been associated with PCOS. By using quantitative label-free proteomics we investigated whether changes in the plasma proteome of pregnant women with PCOS could elucidate the mechanisms behind the pathologies observed in PCOS pregnancies. A total of 169 proteins with ≥2 unique peptides were detected to be differentially expressed between women with PCOS (n = 7) and matched controls (n = 20) at term of pregnancy, out of which 35 were significant (p-value < 0.05).
A pathway analysis revealed that networks related to humoral immune responses, inflammatory responses, cardiovascular disease and cellular growth and proliferation were affected by PCOS. Classification of cases and controls was carried out using principal component analysis, orthogonal projections on latent structure-discriminant analysis (OPLS-DA), hierarchical clustering, self-organising maps and ROC-curve analysis. The most significantly enriched proteins in PCOS were properdin and insulin-like growth factor II. In the dataset, properdin had the best predictive accuracy for PCOS (AUC = 1). Additionally, properdin abundances correlated with AMH levels in pregnant women.
Publication and source details
Original title: Thromboinflammatory changes in plasma proteome of pregnant women with PCOS detected by quantitative label-free proteomics
R. K. Arffman; M. Saraswat; S. Joenväärä; M. Khatun; R. Agarwal; T. Tohmola; I. Sundström-Poromaa; R. Renkonen; T. T. Piltonen
Scientific Reports · 2019
© The Author(s) 2019https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/501100002341Academy of Finland (Suomen Akatemia)315921Piltonen T. T. https://doi.org/10.13039/100008723Suomen Lääketieteen Säätiö (Finnish Medical Foundation)https://doi.org/10.13039/501100006306Sigrid Juséliuksen Säätiö (Sigrid Jusélius Foundation)Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T18:14:29.768210+00:00
DOI: 10.1038/s41598-019-54067-4 · PMC6879536